Showing results for:
Carboplatin is FDA approved to treat people who have certain kinds of cancer, including some blood cancers. Carboplatin may cause temporary loss of hair during treatment. Normal hair growth should return after treatment ends.
Paraplatin® Carboplatin
Cisplatin is FDA approved alone or in combination with other drugs to treat people who have certain types of cancer.
Platinol®-AQ Cisplatin
Dexamethasone, hydrocortisone, methylprednisolone and prednisone are FDA approved corticosteroids that are used to treat many medical problems, including some kinds of cancer. Side effects needing medical attention: Swelling of feet and ankles; muscle weakness; ulcers or stomach pain or burning; easy bruising; wounds that are slow to heal; dizziness; severe headaches; menstrual problems; blood-sugar problems; blurred or decreased vision or seeing halos around lights; sore throat and fever; depression; mood or mental changes; indigestion; sleeplessness; nervousness or restlessness; weight gain.
Prednisone Decadron® Medrol® Methylprednisolone Dexamethasone
Epoetin alfa is indicated forTreatment of anemia due to the effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapyReduction of allogeneic red blood cell transfusions in patients undergoing elective, noncardiac, nonvascular surgery.Epogen is not indicated for use:In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapyIn patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cureIn patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusionIn patients scheduled for surgery who are willing to donate autologous bloodIn patients undergoing cardiac or vascular surgeryAs a substitute for RBC transfusions in patients who require immediate correction of anemia
Epogen® Procrit® EPO Epoetin alfa Epoetin alfa-epbx* Retacrit™ *
Mercaptopurine is FDA approved to treat people who have acute lymphoblastic leukemia as part of a combination regimen.
Purinethol® 6-MP Purixan® Mercaptopurine
Mogamulizumab is FDA approved for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.
Poteligeo® Mogamulizumab
Pacritinib is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L.This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Vonjo™ Pacritinib
Palifermin is FDA approved to help prevent or lessen severe oral mucositis (inflammation of the mucous membrane of the mouth) in patients receiving certain types of blood cancer therapy.
Kepivance® Palifermin
Panobinostat (Farydak) is FDA approved for the treatment of patients with myeloma who have received at least two prior standard therapies, including bortezomib and an immunomodulatory agent. Panobinostat is to be used in combination with bortezomib, a type of chemotherapy, and dexamethasone, an anti-inflammatory medication.
Farydak® Panobinostat
Pegaspargase is FDA approved in combination with other chemotherapy medications to treat people who have acute lymphoblastic leukemia (ALL).
Oncaspar® PEG-L-asparaginase Pegaspargase
Pegfilgrastim is FDA approved toDecrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).Limitations of Use: Pegfilgrastim is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation
Neulasta® Pegfilgrastim G-CSF Fulphila™ * Pegfilgrastim-jmdb* Udenyca™ * Pegfilgrastim-cbqv* Ziextenzo™ * Pegfilgrastim-bmez * Nyvepria Pegfilgrastim-apgf* Fylnetra* Pegfilgrastim-pbbk* Stimufend®* Pegfilgrastim-fpgk*
Pembrolizumab is FDA approved for the treatment of:Adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL)Pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapyAdult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy.Limitation of Use: Pembrolizumab is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
Keytruda® Pembrolizumab
Pentostatin is FDA approved as a single-agent treatment for both untreated and alfa-interferon-refractory hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia (abnormally low white blood count), thrombocytopenia (reduced platelet count), or disease-related symptoms.
Nipent® Pentostatin
Pirtobrutinib is indicated for the treatment ofAdult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Pirtobrutinib Jaypirca®
Plerixafor injection is FDA approved for use along with a granulocyte colony-stimulating factor (G-CSF) medication in preparation for an autologous stem cell transplant in patients with non-Hodgkin lymphoma or myeloma. Plerixafor injection works by causing certain blood cells to move from the bone marrow to the blood so that they can be removed for transplantation.
Mozobil® Plerixafor
Polatuzumab vedotin-piiq is FDA approvedIn combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater.In combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory DLBCL, NOS, after at least two prior therapies.
Polivy® Polatuzumab vedotin-piiq
Pomalidomide is FDA approved to treat people with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is based on response rate. Clinical benefit, such as improvement in survival or symptoms, has not been verified.
Pomalyst® Pomalidomide
Ponatinib is FDA approved for the treatment of adult patients with:Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)Newly diagnosed Ph+ ALL, in combination with chemotherapy.This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL.Chronic Myeloid Leukemia (CML)Chronic phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors.Accelerated phase (AP) or blast phase (BP) CML for whom no other kinase inhibitors are indicated.T315I-positive CML (chronic phase, accelerated phase, or blast phase).Limitations of Use: ICLUSIG is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML.
Iclusig® Ponatinib
Pralatrexate is FDA approved to treat people who have relapsed or refractory peripheral T-cell lymphoma. It is being studied to treat people who have other forms of lymphoma including diffuse large B-cell lymphoma.
Folotyn® Pralatrexate
Procarbazine is FDA approved with other anticancer drugs for the treatment of stage III and IV Hodgkin lymphoma. Procarbazine is used as part of the MOPP (mechlorethamine, Oncovin® [vincristine], procarbazine, prednisone) regimen. This medicine may cause a temporary loss of hair in some people. After treatment with procarbazine has ended, normal hair growth should return.
Matulane® Procarbazine